Investor Alert

Teva Pharmaceutical Industries Ltd. ADR



After Hours

 --Real time quotes

Jan 21, 2022, 6:38 p.m.





-0.04 -0.47%


Volume 51,580

Real time quotes


Today's close

$ 8.64

$ 8.51


-0.13 -1.50%

Day low

Day high




52 week low

52 week high




Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

Fiscal year is January-December. All values ILS millions. 20162017201820192020 5-year trend
Sales/Revenue 84.08B80.52B65.69B60.12B57.29B
Cost of Goods Sold (COGS) incl. D&A 38.56B42.34B35.86B33.32B30.72B
COGS excluding D&A 32.82B34.87B29.24B27.18B25.37B
Depreciation & Amortization Expense 5.74B7.47B6.62B6.14B5.35B
Depreciation 1.92B2.27B2.43B2.17B1.85B
Amortization of Intangibles 3.81B5.19B4.19B3.97B3.51B
Gross Income 45.52B38.18B29.83B26.8B26.57B
20162017201820192020 5-year trend
SG&A Expense 27.85B23.83B19.51B17.16B16.05B
Research & Development 8.1B6.4B4.36B3.6B3.43B
Other SG&A 19.75B17.43B15.15B13.56B12.62B
Other Operating Expense -----
Unusual Expense 11.95B81.2B16.96B11.1B23.29B
EBIT after Unusual Expense (11.95B)(81.2B)(16.96B)(1.46B)(12.78B)
Non Operating Income/Expense (644.91M)3.26B553.67M213.78M137.56M
Non-Operating Interest Income 195.78M302.15M140.22M146.08M82.54M
Equity in Affiliates (Pretax) -----
Interest Expense 2.1B2.83B3.38B3.41B2.6B
Gross Interest Expense 2.1B2.83B3.38B3.41B2.6B
Interest Capitalized -----
Pretax Income 3.16B(66.11B)(9.33B)(4.51B)(15.15B)
Income Tax 2B(6.95B)(701.08M)(990.52M)(577.76M)
Income Tax - Current Domestic 1.85B1.34B2.52B3.15B625.9M
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic 153.55M(8.29B)(3.22B)(4.14B)(1.2B)
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates 30.71M(10.79M)(255.26M)(46.32M)474.59M
Other After Tax Income (Expense) -----
Consolidated Net Income 1.19B(59.17B)(8.89B)(3.56B)(14.1B)
Minority Interest Expense (69.1M)(661.84M)(1.16B)(3.56M)(378.29M)
Net Income 1.26B(58.5B)(7.73B)(3.56B)(13.72B)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries 1.26B(58.5B)(7.73B)(3.56B)(13.72B)
Preferred Dividends 1B935.21M895.22M--
Net Income Available to Common 261.04M(59.44B)(8.63B)(3.56B)(13.72B)
EPS (Basic) 0.27(58.50)(8.45)(3.26)(12.53)
Basic Shares Outstanding 955M1.02B1.02B1.09B1.1B
EPS (Diluted) 0.27(58.50)(8.45)(3.26)(12.53)
Diluted Shares Outstanding 961M1.02B1.02B1.09B1.1B
EBITDA 23.4B21.82B16.94B15.78B15.87B
Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
Powered by StockTwits
Link to MarketWatch's Slice.